[go: up one dir, main page]

MX2019007352A - Composiciones de aminoacidos y metodos para el tratamiento de enfermedades y transtornos musculares. - Google Patents

Composiciones de aminoacidos y metodos para el tratamiento de enfermedades y transtornos musculares.

Info

Publication number
MX2019007352A
MX2019007352A MX2019007352A MX2019007352A MX2019007352A MX 2019007352 A MX2019007352 A MX 2019007352A MX 2019007352 A MX2019007352 A MX 2019007352A MX 2019007352 A MX2019007352 A MX 2019007352A MX 2019007352 A MX2019007352 A MX 2019007352A
Authority
MX
Mexico
Prior art keywords
amino acid
methods
disorders
treatment
acid compositions
Prior art date
Application number
MX2019007352A
Other languages
English (en)
Inventor
Afeyan Raffi
Hamill Michael
Original Assignee
Axcella Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcella Health Inc filed Critical Axcella Health Inc
Publication of MX2019007352A publication Critical patent/MX2019007352A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente descripción proporciona composiciones que comprender entidades de aminoácidos. La descripción también proporciona métodos para mejorar función muscular que comprende la administración de una cantidad eficaz de las proporciones a un sujeto que lo necesita.
MX2019007352A 2016-12-19 2017-12-19 Composiciones de aminoacidos y metodos para el tratamiento de enfermedades y transtornos musculares. MX2019007352A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662436073P 2016-12-19 2016-12-19
US201762443205P 2017-01-06 2017-01-06
US201762491776P 2017-04-28 2017-04-28
US201762545358P 2017-08-14 2017-08-14
US201762576321P 2017-10-24 2017-10-24
PCT/US2017/067368 WO2018118957A1 (en) 2016-12-19 2017-12-19 Amino acid compositions and methods for the treatment of muscle diseases and disorders

Publications (1)

Publication Number Publication Date
MX2019007352A true MX2019007352A (es) 2019-09-05

Family

ID=61025047

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007352A MX2019007352A (es) 2016-12-19 2017-12-19 Composiciones de aminoacidos y metodos para el tratamiento de enfermedades y transtornos musculares.

Country Status (21)

Country Link
US (3) US20180207119A1 (es)
EP (1) EP3554493A1 (es)
JP (1) JP2020502183A (es)
KR (1) KR20190099243A (es)
CN (1) CN110267655A (es)
AU (1) AU2017379825A1 (es)
BR (1) BR112019012476A2 (es)
CA (1) CA3046558A1 (es)
CL (1) CL2019001685A1 (es)
CO (1) CO2019006292A2 (es)
CU (1) CU20190057A7 (es)
EC (1) ECSP19043725A (es)
IL (1) IL267210A (es)
JO (1) JOP20190147A1 (es)
MA (1) MA50763A (es)
MX (1) MX2019007352A (es)
PE (1) PE20191206A1 (es)
PH (1) PH12019501339A1 (es)
TW (1) TWI780096B (es)
WO (1) WO2018118957A1 (es)
ZA (1) ZA201903581B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
EP3615018A1 (en) 2017-04-28 2020-03-04 Axcella Health Inc. Amino acid compositions and their use for the treatment of traumatic brain injury
CN111295187A (zh) 2017-08-14 2020-06-16 胺细拉健康公司 用于治疗肝脏疾病的氨基酸组合物
MX2020001766A (es) * 2017-08-14 2020-07-29 Axcella Health Inc Composiciones de aminoacidos para el tratamiento de lesion neuronal.
CU20200106A7 (es) 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
WO2019246310A1 (en) * 2018-06-20 2019-12-26 Axcella Health Inc. Compositions and methods for the reduction or treatment of inflammation
US11679089B2 (en) 2018-06-20 2023-06-20 Axcella Health Inc. Methods of manufacturing amino acid compositions
MA52971A (fr) 2018-06-20 2021-04-28 Axcella Health Inc Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle
CN112752575A (zh) * 2018-09-27 2021-05-04 雀巢产品有限公司 组氨酸、甘氨酸和其它氨基酸用于预防胰岛素抗性和/或糖尿病的用途
WO2020245299A1 (en) 2019-06-07 2020-12-10 Société des Produits Nestlé S.A. Compositions and methods using one or more autophagy-inducing amino acids to potentiate musculoskeletal effect of one or more anabolic amino acids
US20220184015A1 (en) * 2019-06-20 2022-06-16 Societe Des Produits Nestle S.A. Compositions and methods to potentiate musculoskeletal effect of one or more anabolic amino acids on bone health
KR102456270B1 (ko) * 2019-09-24 2022-10-19 마이오텍사이언스 주식회사 비천연 아미노산 유도체를 함유하는 근감소증의 예방 또는 치료용 약학적 조성물
KR102338447B1 (ko) * 2019-09-24 2021-12-14 마이오텍사이언스 주식회사 비천연 아미노산을 함유하는 근감소증의 예방 또는 치료용 약학적 조성물
US20220331290A1 (en) * 2019-09-24 2022-10-20 Myo-Tec-Sci Pharmaceutical composition for preventing or treating sarcopenia, containing unnatural amino acid
CN110801007A (zh) * 2019-12-17 2020-02-18 苟春虎 老年肌少症营养肽
US20230089723A1 (en) * 2020-03-06 2023-03-23 Axcella Health Inc. Amino acid compositions and methods for muscle and myotube modulation
KR102802853B1 (ko) * 2021-02-26 2025-05-07 이엑스헬스케어 주식회사 피부 유래 엑소좀을 통해 근손실 억제 또는 근생성 촉진 효과를 나타내는 조성물
CN113288890B (zh) * 2021-06-21 2022-02-22 南方医科大学南方医院 N-乙酰-l-半胱氨酸在制备预防和/或治疗运动损伤的药物中的应用
WO2024026307A1 (en) 2022-07-25 2024-02-01 Axcella Health Inc. Biomarker for long covid and fatigue
WO2024030909A1 (en) 2022-08-01 2024-02-08 Axcella Health Inc. Biomarkers of amino acid composition treatment response in long covid
WO2025167857A1 (zh) * 2024-02-06 2025-08-14 南京纽邦生物科技有限公司 用于增强或改善肌肉功能和/或提高运动表现和/或预防或缓解疲劳的方法和组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020090214A (ko) * 2000-02-01 2002-11-30 머슬테크 리서치 앤드 디벨롭먼트, 인크. 근육을 키우거나 강도를 늘리기 위한 α리포산계의보조식품
US20040087490A1 (en) * 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
US20060002913A1 (en) * 2004-06-22 2006-01-05 Gehlsen Kurt R Use of histamine and related compounds to treat disorders affecting muscle function
WO2006105112A2 (en) * 2005-03-29 2006-10-05 Ajinomoto Co., Inc. Amino acid-containing composition for preventing or remedying in the skeletal muscle of aged people
JP2007023921A (ja) * 2005-07-19 2007-02-01 Toyota Motor Corp 内燃機関の制御装置
US20070286909A1 (en) * 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
CN100518815C (zh) * 2007-02-15 2009-07-29 北京苏里曼医药科技有限公司 一种氨基酸组合物
MX2014001996A (es) * 2011-08-19 2014-08-29 Musclepharm Corp Composiciones y metodos para usarse en promover masa corporal magra.
WO2015061607A1 (en) * 2013-10-23 2015-04-30 Whitehead Institute For Biomedical Research Mtorc1 modulation by amino acids and uses thereof

Also Published As

Publication number Publication date
BR112019012476A2 (pt) 2020-04-14
ZA201903581B (en) 2020-12-23
PE20191206A1 (es) 2019-09-10
JOP20190147A1 (ar) 2019-06-18
CO2019006292A2 (es) 2019-06-28
US20180169047A1 (en) 2018-06-21
ECSP19043725A (es) 2019-07-31
CL2019001685A1 (es) 2019-08-30
EP3554493A1 (en) 2019-10-23
KR20190099243A (ko) 2019-08-26
CN110267655A (zh) 2019-09-20
PH12019501339A1 (en) 2019-09-30
WO2018118957A1 (en) 2018-06-28
IL267210A (en) 2019-08-29
TWI780096B (zh) 2022-10-11
US20180207119A1 (en) 2018-07-26
CU20190057A7 (es) 2020-02-04
MA50763A (fr) 2019-10-23
AU2017379825A1 (en) 2019-06-13
US20180169046A1 (en) 2018-06-21
CA3046558A1 (en) 2018-06-28
TW201827068A (zh) 2018-08-01
JP2020502183A (ja) 2020-01-23

Similar Documents

Publication Publication Date Title
PH12019501339A1 (en) Amino acid compositions and methods for the treatment of muscle diseases and disorders
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
ZA202001057B (en) Inhibiting ubiquitin specific peptidase 30
PH12019500204A1 (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
PH12017500746A1 (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
ECSP20011578A (es) Composiciones de aminoácidos para el tratamiento de enfermedad hepática
MX2017005834A (es) Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201992607A1 (ru) Твердые формы берберина урсодезоксихолата, их композиции и способы
MD20160007A2 (ro) Inhibitori ai RORC2 şi metode de utilizare a acestora
EA201691567A1 (ru) Способы лечения легких травм головного мозга
PH12018501443A1 (en) Methods of administering hepcidin
PH12018502161A1 (en) Methods of treatment for cholestatic and fibrotic diseases
MX2020001428A (es) Composiciones de grapiprant y metodos para usar las mismas.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX2019004179A (es) Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer.
PH12019501358A1 (en) Methods of administering hepcidin
NZ724799A (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders
GEP20207145B (en) Combination of trazodone and gabapentin for the treatmen
TW201613926A (en) Inhibitors of bruton's tyrosine kinase
PH12017501693A1 (en) Compositions for the treatment of kidney and/or liver diseases
EA201991504A1 (ru) Композиции на основе аминокислот и способы лечения заболеваний и нарушений мышц
EA201592012A8 (ru) Применение флагеллина для улучшенной химиотерапии
HK40013671A (en) Amino acid compositions and methods for the treatment of muscle diseases and disorders
IN2013MU03429A (es)